Ares Genetic Launches Early Access Program for its Antibiotic Susceptibility Test

  06 November 2019

Ares Genetics, a subsidiary of molecular microbiology diagnostics and syndromic testing company Curetis, has launched an early access program for its molecular antibiotic susceptibility test (AST), that leverages next-generation sequencing (NGS) and artificial intelligence (AI) technologies.

According to the company, the new test has multiple applications ranging from identifying antibiotic susceptibility in the clinical setting and for broader public health applications, as well as for drug developers looking to bring new treatments to market targeting infrectious diseases.

Further reading: Clinical Omics
Author(s): Clinical Omics
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!